Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Sep 1;50(9S):S12-S17.
doi: 10.1097/DSS.0000000000004348. Epub 2024 Jul 30.

Versatility of OnabotulinumtoxinA in Aesthetic Medicine

Mitchell F Brin  1   2 , John Maltman  1 , Mary Ann Chapman  3 , Sara Sangha  1
Affiliations
Review

Versatility of OnabotulinumtoxinA in Aesthetic Medicine

Mitchell F Brin et al. Dermatol Surg. .

Abstract

Background: OnabotulinumtoxinA is an injectable product that was introduced into medicine in the 1970s and has been the subject of thousands of clinical and nonclinical publications.

Objective: To review the data related to the versatility of onabotulinumtoxinA in medical aesthetics.

Methods: PubMed was searched to identify literature evaluating the effects of onabotulinumtoxinA, with preference given to randomized, placebo-controlled trials and safety meta-analyses.

Results: OnabotulinumtoxinA is effective and safe across multiple facial indications, racial and ethnic groups, age groups, genders, and facial line severities. Patient-reported outcomes have been prioritized in aesthetic clinical trials and indicate high patient satisfaction and appearance-related psychological outcomes. Integrated safety meta-analysis and immunogenicity analyses have documented acceptable adverse event rates and low immunogenicity of onabotulinumtoxinA.

Conclusion: OnabotulinumtoxinA is a versatile aesthetic product supported by a strong literature base and positive physician and patient-reported outcomes that reflect a meaningful impact on patient's quality of life.

PubMed Disclaimer

References

    1. Scott AB, Fahn S, Brin MF. Treatment of strabismus and blepharospasm with Botox (onabotulinumtoxinA): development, insights, and impact. Medicine (Baltimore) 2023;102:e32374.
    1. Scott AB, Honeychurch D, Brin MF. Early development history of Botox (onabotulinumtoxinA). Medicine (Baltimore) 2023;102:e32371.
    1. Carruthers J, Carruthers A, Blitzer A, Eadie N, et al. Treatment of glabellar lines with Botox (onabotulinumtoxinA): development, insights, and impact. Medicine (Baltimore) 2023;102:e32375.
    1. Carruthers JD, Carruthers JA. Treatment of glabellar frown lines with C. botulinum-A exotoxin. J Dermatol Surg Oncol 1992;18:17–21.
    1. Brin MF, Blitzer A. The Pluripotential Evolution and Journey of Botox (onabotulinumtoxinA). Medicine (Baltimore) 2023;102:e32373.

MeSH terms

LinkOut - more resources